SVRA Savara Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SVRA

Price (delayed)

$4.705

Market cap

$649.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.33

Enterprise value

$649.75M

Savara is an orphan lung disease company. Its lead program, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Its management ...

Highlights
Savara's equity has increased by 30% YoY but it has decreased by 4.2% from the previous quarter
SVRA's net income is down by 43% YoY and by 12% from the previous quarter
The company's EPS fell by 32% YoY and by 6% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://savarapharma.com
Peers: OPTN OPK ORGO

Key stats

What are the main financial stats of SVRA
Market
Shares outstanding
138.15M
Market cap
$649.99M
Enterprise value
$649.75M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.54
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$50.26M
EBITDA
-$50.09M
Free cash flow
-$51.36M
Per share
EPS
-$0.33
Free cash flow per share
-$0.31
Book value per share
$1.04
Revenue per share
$0
TBVPS
$1.07
Balance sheet
Total assets
$177.56M
Total liabilities
$37.19M
Debt
$26.35M
Equity
$140.37M
Working capital
$155.35M
Liquidity
Debt to equity
0.19
Current ratio
15.66
Quick ratio
15.32
Net debt/EBITDA
0
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-35.9%
Return on equity
-46.3%
Return on invested capital
-35.1%
Return on capital employed
-30.1%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

SVRA stock price

How has the Savara stock price performed over time
Intraday
0.53%
1 week
6.69%
1 month
-1.77%
1 year
148.94%
YTD
0.11%
QTD
-5.52%

Financial performance

How have Savara's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$60.01M
Net income
-$54.7M
Gross margin
N/A
Net margin
N/A
Savara's operating income has plunged by 55% YoY and by 13% from the previous quarter
SVRA's net income is down by 43% YoY and by 12% from the previous quarter

Growth

What is Savara's growth rate over time

Valuation

What is Savara stock price valuation
P/E
N/A
P/B
4.54
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS fell by 32% YoY and by 6% QoQ
The stock's price to book (P/B) is 167% more than its 5-year quarterly average of 1.7 and 26% more than its last 4 quarters average of 3.6
Savara's equity has increased by 30% YoY but it has decreased by 4.2% from the previous quarter

Efficiency

How efficient is Savara business performance
SVRA's ROE is down by 48% YoY and by 4.3% from the previous quarter
SVRA's return on assets is down by 44% year-on-year and by 4.7% since the previous quarter
Savara's ROIC has increased by 23% YoY

Dividends

What is SVRA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SVRA.

Financial health

How did Savara financials performed over time
SVRA's quick ratio is down by 29% YoY and by 18% from the previous quarter
SVRA's current ratio is down by 29% year-on-year and by 17% since the previous quarter
The debt is 81% smaller than the equity
Savara's equity has increased by 30% YoY but it has decreased by 4.2% from the previous quarter
The debt to equity has contracted by 21% YoY but it has grown by 6% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.